Last reviewed · How we verify
Perindopril or Perindopril/Indapamide
Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload.
Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload. Used for Hypertension, Heart failure.
At a glance
| Generic name | Perindopril or Perindopril/Indapamide |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This action results in vasodilation and a decrease in peripheral resistance, which in turn reduces blood pressure and heart workload. Additionally, ACE inhibitors like perindopril have been shown to have protective effects on the kidneys and heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension (PHASE3)
- European Blood Pressure Intensive Control After Stroke (PHASE2)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients (NA)
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: